The Online Investor
Healthcare M&A image Healthcare M&A » By The Online Investor Staff, updated Sat., Aug. 17, 10:31 AM Recent mergers and acquisitions in the Healthcare M&A category.

Slide #43. Mallinckrodt Pharmaceuticals Questcor Pharmaceuticals

Acquirer: Mallinckrodt Pharmaceuticals (MNK)
Acquiree: Questcor Pharmaceuticals (QCOR)
Details: Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceuticals company, and Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), a high-growth biopharmaceutical company, today announced that they have entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction valued at approximately $5.6 billion. The transaction was unanimously approved by the Boards of Directors of both companies. Subject to customary closing conditions, the transaction is currently expected to be completed in the third calendar quarter of 2014.

Mallinckrodt develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare disease in areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology, immunotherapy and neonatal respiratory critical care therapies, analgesics and gastrointestinal products. Co. operates its business in two reportable segments: Specialty Brands, which markets branded pharmaceutical products for autoimmune and rare diseases; and Specialty Generics and Amitiza, which provides specialty generic drugs, active pharmaceutical ingredients, and Amitiza® (lubiprostone), a product in the gastrointestinal market.

MNK SEC Filing Email Alerts Service


Open the MNK Page at The Online Investor »

Mallinckrodt develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare disease in areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology, immunotherapy and neonatal respiratory critical care therapies, analgesics and gastrointestinal products. Co. operates its business in two reportable segments: Specialty Brands, which markets branded pharmaceutical products for autoimmune and rare diseases; and Specialty Generics and Amitiza, which provides specialty generic drugs, active pharmaceutical ingredients, and Amitiza® (lubiprostone), a product in the gastrointestinal market.

MNK SEC Filing Email Alerts Service


Open the QCOR Page at The Online Investor »

Company Name: 
Mallinckrodt Plc
Stock buyback: 
MNK buyback
Website: 
www.mallinckrodt.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding MNK: 
51
Total Market Value Held by ETFs: 
$72.31M
Total Market Capitalization: 
$390.00M
% of Market Cap. Held by ETFs: 
18.54%
Company Name: 
Questcor Pharmaceuticals Inc
Stock buyback: 
QCOR buyback
Website: 
www.questcor.com
Sector: 
Drugs & Pharmaceuticals
 

Quotes delayed 20 minutes


Healthcare M&A - Slide 43 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2019, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.